Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Gold auf 4.000 USD? Goldman Sachs sagen Ja - und bei Forge sitzt der Ex-CFO von Newmont mit am Tisch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CTP6 | ISIN: US00509G2093 | Ticker-Symbol:
NASDAQ
21.04.25
21:59 Uhr
1,065 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACUMEN PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACUMEN PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ACUMEN PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.04.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting3
27.03.Acumen Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
27.03.Acumen Pharmaceuticals, Inc. - 10-K, Annual Report1
27.03.Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline2
27.03.Acumen Pharmaceuticals reports FY results1
27.03.Acumen Pharmaceuticals, Inc. - 8-K, Current Report1
26.03.Preview: Acumen Pharmaceuticals' Earnings2
26.03.Acumen Pharmaceuticals completes Phase 2 trial enrollment2
ACUMEN PHARMACEUTICALS Aktie jetzt für 0€ handeln
26.03.Acumen Pharmaceuticals schließt Patientenrekrutierung für Phase-2-Studie ab1
26.03.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease105NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
► Artikel lesen
20.03.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 20253
19.03.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers98Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration supports further clinical development Development of...
► Artikel lesen
09.01.Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings3
11.11.24Acumen Pharmaceuticals Earnings Preview2
06.11.24Acumen Pharmaceuticals appoints new regulatory chief1
06.11.24Acumen Pharmaceuticals ernennt neue Regulierungschefin3
05.11.24Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 20241
31.10.24Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th ...173Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures...
► Artikel lesen
29.07.24Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease123NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
► Artikel lesen
08.05.24Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease163CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1